Impact of ND0612 on Levodopa-Induced Dyskinesia in Parkinson’s Disease: Post hoc Analyses From a Randomized, Active-Controlled Study
Objective: To evaluate dyskinesia-related outcomes between optimized subcutaneously administered levodopa/carbidopa (ND0612) + immediate-release levodopa/carbidopa (IR-LD/CD) vs optimized oral IR-LD/CD in patients with Parkinson’s disease (PD).…Safety and tolerability of overnight switching from Eetacapone to Opicapone in fluctuating Parkinson’s disease: An open-label preliminary trial in Koreans
Objective: Objectives: 1. Efficacy - Opicapone 50mg qd. to determine effectiveness of optimal dose for switching. 2. Tolerability and safety - compare symptoms and adverse…Clinical Profile of Motor Complications in Parkinson’s Disease Patients at A National Tertiary Hospital In Indonesia
Objective: To analyse factors associated with motor complications in Parkinson's disease at a national tertiary referral hospital in Indonesia. Background: As Parkinson's disease progresses, levodopa…Effects of ectopic dopamine D2 autoregulation of raphe-striatal projecting neurons on established L-DOPA-mediated behaviors in a hemiparkinsonian rat model
Objective: Levodopa (LD) is the standard treatment for Parkinson’s Disease (PD) despite risk of LD-induced dyskinesia (LID) development within a decade of treatment. Serotonergic (5-HT)…Basal ganglia theta oscillation as a predictor of levodopa-induced dyskinesias
Objective: To investigate the temporal and spatial relationship between local field potential (LFP) changes and dyskinesia development. Background: Levodopa-induced dyskinesias (LID) are an important burden…The Differences in the Perception of Parkinson’s Disease-related Motor Complications between Patients and Physicians
Objective: This study aimed to evaluate the differences in the perception of Parkinson’s disease (PD)-related motor complications by utilizing questionnaires answered by both PD patients…Efficacy and Safety of Controlled-Release Levodopa in Parkinson’s Disease: a Systematic Review and Meta-Analysis
Objective: To evaluate the efficacy and safety of controlled-release levodopa (CRLD) compared with standard release levodopa (SRLD) in patients with Parkinson’s Disease (PD) and motor…Clinical, Neurophysiological, and Biological Insights into Levodopa-Induced Dyskinesias
Objective: The aim of this study was to determine the clinical, neurophysiological and biological features of Parkinson's Disease (PD) patients with L-Dopa-induced dyskinesias (LIDs). Background:…Correlation Between Mild Cognitive Impairment and Levodopa Induced Dyskinesia in Parkinson’s Disease Patients
Objective: The aim of this study is to compare the level of mild cognitive impairment in Parkinson’s disease patients with and without levodopa-induced dyskinesia. Additionally,…Clinical benefit of Opicapone in patients with different Parkinson disease phenopytes. The OPTIMO study
Objective: To assess the clinical benefit induced by opicapone (OPC) as an add-on therapy to levodopa in fluctuating Parkinson’s disease (PD) patients with special focus…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 44
- Next Page »